Ad hoc releases are announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
View Featured news and Pulse updates.
Header
Newsroom
Showing 1851 results
June 2019
-
Press release
Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show
Almost 90% of patients had no radiographic progression of psoriatic arthritis (PsA) at 2 years with Cosentyx (secukinumab) 300mg[1] Data at 2 years demonstrate over 50% of adults with… -
Press release
Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis
First-of-its-kind data shows efficacy and safety of a biologic in the management of axial manifestations of psoriatic arthritis (PsA), which affect up to an estimated 35 million people worldwide[1… -
Ad hoc release
Novartis announces new leader of Pharmaceuticals Business Unit
Marie-France Tschudin, an experienced Novartis leader, appointed to President, Novartis Pharmaceuticals Basel, June 7, 2019 - Novartis announced today that Marie-France Tschudin, currently… -
Ad hoc release
Novartis stellt neue Leiterin der Pharmaceuticals Business Unit vor
Marie-France Tschudin, erfahrene Novartis Führungsperson, zur Präsidentin von Novartis Pharmaceuticals ernannt Basel, 7. Juni 2019 - Novartis kündigte heute an, dass Marie-France Tschudin,… -
Press release
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare®
Advanced Accelerator Applications Receives Positive CHMP Opinion for LysaKare® for Reduction of Kidney Exposure to Radiation During Peptide Receptor Radionuclide Therapy with Lutetium (177Lu)… -
Press release
Novartis presents first-of-its-kind histology data with iscalimab (CFZ533) suggesting the extended survival of transplanted organs may be possible
Data show 60% of iscalimab-treated transplant patients have normal kidney histology at least 1 year after transplant vs 0% with tacrolimus (current standard of care)[1] Less than half of donated… -
Press release
Long-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®
Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine… -
Story Discovery
Toward improving the health and longevity of transplanted organs
Novartis researchers are working to extend the life of organ transplants
-
Press release
Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials
Primary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (… -
Press release
Xolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
In the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate… -
Press release
Novartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trial
Kisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1] After a median of 42 months follow-up, the survival rate was 70.2% for…